Technology area: Biotechnology & Pharmaceuticals
4 pending office actions • 3 art units • 4 examiners • 0 of 4 (0%) have an AI response strategy ready
Nirvana Sciences Inc. has 4 pending office actions within the Biotechnology & Pharmaceuticals technology area. These matters are distributed among 4 distinct examiners, which suggests that each case is receiving an independent review. However, these examiners are located within 3 distinct art units, indicating that some examiners share the same departmental oversight. This distribution across 3 distinct art units shows a concentrated technical focus for the company, as multiple matters are being evaluated within the same specialized groups. Practitioners should account for the different perspectives of the examiners while also noting the commonalities that may exist within the art units.
LEWOCZKO, EVAN MICHAEL is the busiest examiner for this portfolio, currently holding 1 busiest examiner pending action. Since there are multiple examiners for the active matters, the workload is spread across the individuals involved. The 4 pending office actions in Biotechnology & Pharmaceuticals represent the current active prosecution pipeline for Nirvana Sciences Inc., with 1 busiest examiner pending action assigned to the lead examiner. This structure allows for a diversified prosecution strategy where the outcome of one matter is less likely to be influenced by the specific biases of a single examiner. Practitioners can leverage the involvement of 3 distinct art units to identify potential trends in how the USPTO is treating the company's specific technical niche.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 1 (25%) |
| Double-patenting + other | 3 (75%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| LEWOCZKO, EVAN MICHAEL | 1 | — | — |
| WELLS, LAUREN QUINLAN | 1 | 49.4% | +59.7% |
| BAEK, JONGHWAN NMN | 1 | 50.0% | +0.0% |
| CRAIG, KAILA ANGELIQUE | 1 | 33.8% | +25.2% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18571684 | BACTERIOCHLORINS WITH BETA-PYRROLE LINKER | WELLS, LAUREN QUINLAN | — |
| 17612971 | NARROW EMISSION DYES, COMPOSITIONS COMPRISING SAME, AND METHODS FOR MAKING AND USING SAME | CRAIG, KAILA ANGELIQUE | — |
| Art Unit | Apps |
|---|---|
| 1618 | 2 |
| 1612 | 1 |
| 1622 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18581223 | METALLOHYDROPORPHYRINS FOR PHOTOACOUSTIC IMAGING | LEWOCZKO, EVAN MICHAEL | 1612 | §103§112DP | Non-Final OA | — | Pending | Feb 19, 2024 |
| 18571684 | BACTERIOCHLORINS WITH BETA-PYRROLE LINKER | WELLS, LAUREN QUINLAN | 1622 | §103DP | Non-Final OA | — | Pending | Dec 18, 2023 |
| 18271010 | METALLOHYDROPORPHYRINS FOR PHOTOACOUSTIC IMAGING | BAEK, JONGHWAN NMN | 1618 | §102§103§112DP | Non-Final OA | 33d | Pending | Jul 05, 2023 |
| 17612971 | NARROW EMISSION DYES, COMPOSITIONS COMPRISING SAME, AND METHODS FOR MAKING AND USING SAME | CRAIG, KAILA ANGELIQUE | 1618 | §103 | Final Rejection | — | Pending | Nov 19, 2021 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialNirvana Sciences Inc. has 4 pending office actions as of October 2026, spread across 3 art units and 4 examiners.
Evan Michael Lewoczko has the most, with 1 of Nirvana Sciences Inc.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
